On Feb. 3, 2021, Bristol-Myers and The Rockefeller University announced an agreement under which Bristol Myers Squibb was granted a global exclusive license to develop, manufacture and commercialize Rockefellerﾒs novel monoclonal antibody (ﾓmAbﾔ) duo treatment that neutralizes the SARS-CoV-2 virus for therapy or prevention of COVID-19.